KATHLEEN LALLY: Open Payments
NPI 1508365842 · NORMAL, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,721 in 122 payments from 27 companies in 2025. Trend: 2023 $2,407 · 2024 $2,582 · 2025 $3,721
Food & beverage: $2,740Travel & lodging: $846Education: $134
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $1,278 |
| CSL Behring | 20 | $308 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $295 |
| GENZYME CORPORATION | 12 | $269 |
| AstraZeneca Pharmaceuticals LP | 10 | $263 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $141 |
| Genentech USA, Inc. | 5 | $127 |
| Incyte Corporation | 1 | $100 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
| GlaxoSmithKline, LLC. | 5 | $97 |
Products named: DUPIXENT, AIRSUPRA, Xolair, NEFFY, CUVITRU, Hizentra, Andembry, AYVAKIT.
Industry payments across IL — which companies pay providers there.
